MD-Logic Artificial Pancreas for Automatic Type 1 Diabetes Meals Management

Type 1 Diabetes Clinical Trial

Official title:

MD-Logic Artificial Pancreas for Automatic Type 1 Diabetes Meals Management

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01901913
• Other study ID #: rmc007418ctil
• Status: Completed
• Phase: N/A
• First received: July 9, 2013
• Last updated: April 15, 2015
• Start date: October 2013
• Est. completion date: April 2015

Study information

• Verified date: November 2014
• Source: Rabin Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The MDLAP (MD-Logic Artificial Pancreas)system is as an automatic system to regulate glucose levels by delivery of insulin operable in clinical trial settings. The safety of the system was proved in previous inpatient and outpatient trials in large number of patients. In the current study we aim to optimize post-prandial closed-loop glycemic control by developing an automated MD-bolus calculator and to evaluate its safety and efficacy in controlling postprandial blood glucose when used together with the MD-Logic artificial pancreas system in type 1 diabetes patients.

The study will consist of a pilot study with two segments and a main study segment. The aim of each segment is detailed below:

1. Pilot Study - Segment 1 - Hybrid meal bolus ratio The aim of this segment is to evaluate the efficacy and safety of different pre-meal bolus dosing compared to full closed-loop operation with no meal announcement.

2. Pilot Study - Segment 2 - Insulin dosing during meal In this segment we would like to test the optimal distribution of insulin delivery during the meal.

3. Main study - Segment 3 - Automatic bolus calculator In this main segment of the study we will use the results and conclusions from the previous two pilot segments to develop the MD-Bolus Calculator for closed-loop control use. The safety and efficacy of this automated insulin bolus calculator will be tested in a randomized cross-over study that will compare postprandial glycemic control under MDLAP with and without the use of the MD-Bolus Calculator.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 14 Years to 25 Years

Eligibility

Inclusion Criteria:

• Diabetes type 1

• Age 14-25 years

->1yr since diagnosis

• Insulin infusion pump therapy for at least 3 months

• HbA1c at inclusion =10%

• BMI < 95th percentile for age and sex

• Patients willing to follow study instructions

Exclusion Criteria:

• Any condition that influence intestinal absorption or motility such as diabetic gastroparesis, celiac disease or malabsorptive states that could affect postprandial glucose absorption.

• any episode of diabetic ketoacidosis within the month prior to study entry and/or severe hypoglycaemia resulting in seizure or loss of consciousness in the month prior to enrolment

• any concomitant disease that may influence metabolic control

• participation in any other interventional study

• known or suspected allergy to trial products

• any significant diseases (such as preexisting seizures or epilepsy) or conditions including psychiatric disorders, eating disorder and substance abuse that in the opinion of the investigator is likely to affect the subjects ability to complete the study or compromise patients safety

• Female subject who is pregnant or planning to become pregnant within the planned study duration.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Device:
• MD-bolus calculator for pre-meal bolus

• No MD-bolus calculator for pre-meal bolus

Locations

Country	Name	City	State
Israel	Schneider Children's Medical Center	Petah-Tikva

Sponsors (1)

Lead Sponsor	Collaborator
Rabin Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area under the curve above 180 mg/dl (10 mmol/l)		4 hours postprandial	No
Secondary	Time within range of 70-180 mg/dl over 4 hours from the beginning of the meal		4 hours postprandial	No
Secondary	The incremental glucose rise from premeal to peak postprandial level		4 hours postprandial	No
Secondary	Number of hypoglycemic events below 70 mg/dl (3.9 mmol/l)		4 hours postprandial	Yes
Secondary	The percentage of subjects who reached the desired glucose target (70-180 mg/dl) 4 hours postprandial.		4 hours postprandial	No
Secondary	Percentage of time spent below 70 mg/dl (3.9mmol/l)		4 hours postprandial	Yes
Secondary	Percentage of time spent above 180, 250, (10, 13.9 mmol/l)		4 hours postprandial	No